_1588141906819.png?format=webp&height=120&width=120){kind=logo}
ROME Therapeutics - About the company
ROME Therapeutics is an acquired company based in Cambridge (United States), founded in 2020. It operates as a Developer of therapeutics for cancer and autoimmune disorders. ROME Therapeutics has raised $199M in funding from investors like Google Ventures, Arch Venture Partners and Bristol-Myers Squibb. The company has 4022 active competitors, including 1359 funded and 908 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Alnylam.
Company Details
Developer of therapeutics for cancer and autoimmune disorders. The company is developing drugs based on the power of the repeatome that targets the repetitive sequences of nucleic acids (repeats or junk DNA).
- Website
- rometx.com
- Social
- Email ID
- *****@rometx.com
- Registered Address
- 610 MAIN STREET, CAMBRIDGE, MA 02139
Key Metrics
Founded Year
2020
Location
Cambridge, United States
Stage
Acquired
Total Funding
$199M in 3 rounds
Latest Funding Round
Investors
Ranked
363rd among 4022 active competitors
Similar Companies
Exit Details
Acquired by Pretzel (Jan 12, 2026)
Legal entities associated with ROME Therapeutics
ROME Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Rome Therapeutics, Inc. CIN: 83-3633163 , United States, Active | Feb 11, 2019 | - | 32 (As on Dec 31, 2021) | - |
ROME Therapeutics's acquisition details
ROME Therapeutics got acquired by Pretzel on Jan 12, 2026.
Click here to take a look at ROME Therapeutics's acquisition in detail
Sign up to download ROME Therapeutics' company profile
ROME Therapeutics's funding and investors
ROME Therapeutics has raised a total funding of $199M over 3 rounds. Its first funding round was on Apr 27, 2020. Its latest funding round was a Series B round on Sep 12, 2023 for $*****. 9 investors participated in its latest round. ROME Therapeutics has 15 institutional investors.
Here is the list of recent funding rounds of ROME Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 12, 2023 | 5943094 | Series B | 9504268 | 8949183 | 4144331 | 2256539 |
Sep 14, 2021 | 6656345 | Series B | 2078144 | 8548432 | 6134231 | |
Apr 27, 2020 | 7797046 | Series A | 2705891 | 4683003 | 4042344 |
Access funding benchmarks and valuations. Sign up today!View details of ROME Therapeutics's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ROME Therapeutics's Competitors and alternates
Top competitors of ROME Therapeutics include Jazz Pharmaceuticals, BeiGene and Alnylam. Here is the list of Top 10 competitors of ROME Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 80/100 | |
4th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
5th | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
6th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
7th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
8th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
9th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
363rd | _1588141906819.png?devicePixelRatio=2&height=30&width=30){kind=logo} ROME Therapeutics 2020, Cambridge (United States), Acquired | Developer of therapeutics for cancer and autoimmune disorders | $199M | 57/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on ROME Therapeutics's competitors? Click here to see the top ones
ROME Therapeutics's Investments and acquisitions
ROME Therapeutics has made no investments or acquisitions yet.
Reports related to ROME Therapeutics
Here is the latest report on ROME Therapeutics's sector:
News related to ROME Therapeutics
Filter this listMedia has covered ROME Therapeutics for 1 event in last 1 year.
•
Pretzel Therapeutics Buys Rome and Its 'Dark Genome' WorkEndpoints•Jan 13, 2026•Pretzel, ROME Therapeutics
•
ROME Therapeutics Appoints Heike Keilhack, Ph.D., as Chief Scientific OfficerBusiness Wire•Jan 04, 2024•ROME Therapeutics, Ribon Therapeutics
•
ROME Expands Leadership Team with the Appointment of Industry Veteran Kyle Kuvalanka as Chief Financial Officer and Chief Business OfficerBusiness Wire•Oct 04, 2023•ROME Therapeutics, Goldfinch
•
Rome Therapeutics raises $72M in series B financingLabPulse.com•Sep 21, 2023•Bristol-Myers Squibb, ROME Therapeutics, Johnson & Johnson, Eurofarma
•
With latest fundraise, Rome Therapeutics works to drug the ‘dark genome’BioPharmaDive•Sep 12, 2023•ROME Therapeutics, Johnson & Johnson, Bristol-Myers Squibb, Sanofi and 12 others
•
ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early DevelopmentACROFAN•Mar 09, 2023•ROME Therapeutics
•
ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune DiseaseBusiness Wire•Nov 10, 2022•ROME Therapeutics
•
ROME Therapeutics Appoints Industry Veteran Jeff Hatfield as Chair of Board of DirectorsBusiness Wire•Jul 18, 2022•ROME Therapeutics, Vividion Therapeutics
•
ROME Therapeutics Appoints Nurjana Bachman, Ph.D., as Senior Vice President, Corporate Development and StrategyBusiness Wire•Apr 26, 2022•ROME Therapeutics, Foundation Medicine
•
ROME Therapeutics Announces Preclinical Data Demonstrating Inhibition of Endogenous Reverse Transcriptase Activity Blocks Immune Response in Autoimmune Disease ModelsBusiness Wire•Nov 08, 2021•ROME Therapeutics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about ROME Therapeutics
Explore our recently published companies
- Entrans - Prague based, 2003 founded, Funding Raised company
- Evolvez - New York based, 2019 founded, Unfunded company
- Kognico - New York based, 2003 founded, Unfunded company
- Happy Shark Media - New York based, 2019 founded, Unfunded company
- Spartan Institutional Research - New York based, 1996 founded, Unfunded company
- Ayoki Fabricon - Pune based, 1984 founded, Unfunded company
